Lawyers

Serdar Inci

Lawyers
Associate in our Capital Markets practice, based in London.

Serdar advises U.S. and international clients on the full spectrum of equity and debt capital markets transactions. On the equity side, he represents issuers, selling shareholders and underwriters in U.S. and cross-border IPOs, SPAC deals and private placements. On the debt side, he advises on SEC-registered and unregistered offerings of high-yield, investment-grade, and regulatory capital instruments, as well as liability management transactions.

His work spans the Nordics, Switzerland, Austria, Germany, the United Kingdom, United States, South Africa and India. He advises VC funds, family offices, listed and private multinationals, global financial institutions, and SPAC sponsors. Serdar’s sector experience includes biotech, healthcare, energy, fintech, consumer products, natural resources, infrastructure, industrials, automotive and sovereigns.

He is bilingual in German and English.

Languages

German

Languages

German

Experience

Selected experience includes:

Equity
  • Birkenstock on three transactions since 2025: a $845 m secondary offering with a $200 m concurrent share repurchase; a $250 m accelerated share repurchase; and a $1.1 bn secondary offering with a $500 m concurrent share repurchase (2026)
  • Viessmann, as selling shareholder, on two secondary offerings of Carrier Global shares totaling $1.35 bn, including a concurrent repurchase by Carrier (2025-2026)
  • Guardian Metal Resources on its $68 m U.S. IPO and NYSE American listing (2026)
  • EQT AB on its $1.4 bn IPO and Nasdaq Stockholm listing, and IONOS Group on its €447 m IPO and Frankfurt listing
  • SPAC IPOs for Forbion European Acquisition Corp. ($110 m), Mountain & Co. I Acquisition Corp. ($230 m) and Target Global Acquisition I Corp. ($200 m), and ACG Metals on the $200 m private placement for its de-SPAC acquisition of the Gediktepe mine
  • SEAS NVE on its DKK 5.4 bn block sale of Ørsted shares, and Nordic private placements and follow-ons for Oncopeptides, Xspray Pharma and Centogene
  • The underwriters on:
    • Haleon: three secondary offerings totaling $9.1 bn (2024-2025)
    • Bovis Homes (£152.2 m placing), Investcorp India Acquisition Corp. ($258.5 m IPO) and Levere Holdings Corp. ($250 m IPO)
Debt
  • Aker BP on three bond offerings totaling $4 billion and a $1.1 billion cash tender offer
  • Amrize on its $3.4 billion debut bond offering and $1.8 billion exchange offers for Holcim bonds in connection with the Amrize spin-off
  • NatWest Group on SEC-registered bond offerings totaling $3.8 billion, a $1.9 billion cash tender offer and its $5 billion U.S. commercial paper program
  • Smith+Nephew on its $1 billion debut SEC-registered bond offering
  • Kantar on its $1.3 billion high yield bond offering
  • Ferguson on its $600 million bond offering
  • Roche on its $7.5 billion U.S. commercial paper program
  • The underwriters on:
    • numerous bond offerings by Anglo American, totaling more than $4 billion
    • SEC-registered subordinated Tier 2 notes offerings by Deutsche Bank, totaling more than $4 billion
    • numerous SEC-registered notes offerings by Oesterreichische Kontrollbank, totaling more than $3.5 billion
    • the $2.4 billion SEC-registered notes offering by British American Tobacco
    • bond offerings by U.S. subsidiaries of National Grid (KeySpan Gas East, Boston Gas and Niagara Mohawk Power), totaling $1.3 billion
    • the $750 million bond offering and concurrent cash tender offer by AngloGold Ashanti
View more experience

Education

LL.M., Columbia Law School
  • Dr. Theo Waigel Scholarship
  • Dr. Walter Oppenhoff Scholarship
  • ERP Scholarship
  • Senior Editor, Columbia Journal of European Law
Ph.D., University of Cologne
  • summa cum laude
  • Studienstiftung Scholarship
  • Editor-In-Chief, Cologne Business Law Review
J.D., University of Cologne
  • third in class
  • Dean's Award for Academic Excellence

Qualifications and admissions

  • State of New York

Not admitted in England & Wales

Back to top